Bibliotecas PUC-SP - Busca Integrada

Feasibility of Adjuvant Treatment with Abemaciclib—Real-World Data from a Large German Breast Center

od Dominik Dannehl, Lea L. Volmer, Martin Weiss, Sabine Matovina, Eva-Maria Grischke, Ernst Oberlechner, Anna Seller, Christina B. Walter, Markus Hahn, Tobias Engler, Sara Y. Brucker, Andreas D. Hartkopf
izdano v Journal of Personalized Medicine (2022-03-01)

Recurrence Score^® Result Impacts Treatment Decisions in Hormone Receptor-Positive, HER2-Negative Patients with Early Breast Cancer in a Real-World Setting—Results of the...

od Dominik Dannehl, Tobias Engler, Lea L. Volmer, Annette Staebler, Anna K. Fischer, Martin Weiss, Markus Hahn, Christina B. Walter, Eva-Maria Grischke, Falko Fend, Florin-Andrei Taran, Sara Y. Brucker, Andreas D. Hartkopf
izdano v Cancers (2022-10-01)

The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrials

od Monika Graeser, Nadia Harbeck, Oleg Gluz, Rachel Würstlein, Christine zu Eulenburg, Claudia Schumacher, Eva-Maria Grischke, Helmut Forstbauer, Moritz Dimpfl, Michael Braun, Matthias Christgen, Hans Heinrich Kreipe, Jochem Potenberg, Raquel von Schumann, Bahriye Aktas, Cornelia Kolberg-Liedtke, Sherko Kümmel, Ulrike Nitz
izdano v Breast (2021-10-01)

Efficacy of Electrochemotherapy in Breast Cancer Patients of Different Receptor Status: The INSPECT Experience

od Claudia Di Prata, Matteo Mascherini, Alastair MacKenzie Ross, Barbara Silvestri, Erika Kis, Joy Odili, Tommaso Fabrizio, Rowan Pritchard Jones, Christian Kunte, Antonio Orlando, James Clover, Siva Kumar, Francesco Russano, Paolo Matteucci, Tobian Muir, Francesca de Terlizzi, Julie Gehl, Eva-Maria Grischke
izdano v Cancers (2023-06-01)

Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial

od Cornelia Kolberg-Liedtke, Friedrich Feuerhake, Madlen Garke, Matthias Christgen, Ronald Kates, Eva Maria Grischke, Helmut Forstbauer, Michael Braun, Mathias Warm, John Hackmann, Christoph Uleer, Bahriye Aktas, Claudia Schumacher, Sherko Kuemmel, Rachel Wuerstlein, Monika Graeser, Ulrike Nitz, Hans Kreipe, Oleg Gluz, Nadia Harbeck
izdano v Breast Cancer Research (2022-09-01)

Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer

od Nadia Harbeck, Raquel von Schumann, Ronald Ernest Kates, Michael Braun, Sherko Kuemmel, Claudia Schumacher, Jochem Potenberg, Wolfram Malter, Doris Augustin, Bahriye Aktas, Helmut Forstbauer, Joke Tio, Eva-Maria Grischke, Claudia Biehl, Cornelia Liedtke, Sanne Lysbet De Haas, Regula Deurloo, Rachel Wuerstlein, Hans Heinrich Kreipe, Oleg Gluz
izdano v Cancers (2021-09-01)

Which Patients Do We Need to Test for BRCA1/2 Mutation? Feasibility of Adjuvant Olaparib Treatment in Early Breast Cancer–Real-World Data from Two Large German Breast Centers

od Dominik Dannehl, Tobias Engler, Léa Louise Volmer, Christian Martin Tegeler, Julia Fusshoeller, Emma Gabrysch, Kenneth Eissler, Anna Seller, Eva-Maria Grischke, Markus Hahn, Ines Gruber, Fabienne Schochter, Kerstin Pfister, Kristina Veselinovic, Elena Leinert, Brigitte Rack, Visnja Fink, Wolfgang Janni, Sara Yvonne Brucker, Andreas Daniel Hartkopf, Henning Schäffler
izdano v Cancers (2023-07-01)

Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial

od Eva-Maria Grischke, Nadia Harbeck, Michael Braun, Katarzyna Jozwiak, Michael Hauptmann, Claudia Schumacher, Monika Graeser, Friedrich Feuerhake, Oleg Gluz, Valery Volk, Matthias Christgen, Sherko Kuemmel, Helmut Forstbauer, Mathias Warm, John Hackmann, Christoph Uleer, Bahriye Aktas, Cornelia Kolberg-Liedtke, Ronald Kates, Rachel Wuerstlein, Ulrike Nitz, Hans Heinrich Kreipe
izdano v Journal for ImmunoTherapy of Cancer (2021-05-01)

The run-in phase of the prospective WSG-ADAPT HR+/HER2– trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized t...

od Ulrike Nitz, Oleg Gluz, Hans H. Kreipe, Matthias Christgen, Sherko Kuemmel, Frederick L. Baehner, Steven Shak, Bahriye Aktas, Michael Braun, Kerstin Lüdtke-Heckenkamp, Helmut Forstbauer, Eva-Maria Grischke, Benno Nuding, Maren Darsow, Claudia Schumacher, Katja Krauss, Wolfram Malter, Marc Thill, Mathias Warm, Rachel Wuerstlein, Ronald E. Kates, Nadia Harbeck
izdano v Therapeutic Advances in Medical Oncology (2020-11-01)

TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer

od Isabel Grote, Stephan Bartels, Leonie Kandt, Laura Bollmann, Henriette Christgen, Malte Gronewold, Mieke Raap, Ulrich Lehmann, Oleg Gluz, Ulrike Nitz, Sherko Kuemmel, Christine zuEulenburg, Michael Braun, Bahriye Aktas, Eva‐Maria Grischke, Claudia Schumacher, Kerstin Luedtke‐Heckenkamp, Ronald Kates, Rachel Wuerstlein, Monika Graeser, Nadia Harbeck, Matthias Christgen, Hans Kreipe
izdano v Cancer Medicine (2021-12-01)

Immunomodulatory gene networks predict treatment response and survival to de-escalated, anthracycline-free neoadjuvant chemotherapy in triple-negative breast cancer in the WSG-ADAP...

od Darren Korbie, Clare Stirzaker, Oleg Gluz, Christine zu Eulenburg, Ulrike Nitz, Matthias Christgen, Sherko Kuemmel, Eva-Maria Grischke, Helmut Forstbauer, Michael Braun, Mathias Warm, John Hackmann, Christoph Uleer, Bahriye Aktas, Claudia Schumacher, Rachel Wuerstlein, Enrico Pelz, Hans Heinrich Kreipe, Susan J. Clark, Matt Trau, Monika Graeser, Nadia Harbeck
izdano v Molecular Cancer (2025-03-01)

Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study

od Nicholas C. Turner, A. Douglas Laird, Melinda L. Telli, Hope S. Rugo, Audrey Mailliez, Johannes Ettl, Eva-Maria Grischke, Lida A. Mina, Judith Balmaña, Peter A. Fasching, Sara A. Hurvitz, Julia F. Hopkins, Lee A. Albacker, Jijumon Chelliserry, Ying Chen, Umberto Conte, Andrew M. Wardley, Mark E. Robson
izdano v npj Breast Cancer (2023-10-01)

Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials

od Monika Graeser, Simone Schrading, Oleg Gluz, Kevin Strobel, Christopher Herzog, Lale Umutlu, Alex Frydrychowicz, Dorothea Rjosk-Dendorfer, Rachel Würstlein, Ralph Culemann, Christine Eulenburg, Jascha Adams, Henrik Nitzsche, Anna Prange, Sherko Kümmel, Eva-Maria Grischke, Helmut Forstbauer, Michael Braun, Jochem Potenberg, Raquel von Schumann, Bahriye Aktas, Cornelia Kolberg-Liedtke, Nadia Harbeck, Christiane K. Kuhl, Ulrike Nitz
izdano v Breast Cancer Research (2021-03-01)

GAIN2 trial overall survival with intense versus tailored dose dense chemotherapy in early breast cancer

od Volker Möbus, Hans-Joachim Lück, Ekkehart Ladda, Peter Klare, Knut Engels, Marcus Schmidt, Andreas Schneeweiss, Eva-Maria Grischke, Grischa Wachsmann, Helmut Forstbauer, Michael Untch, Frederik Marmé, Jens-Uwe Blohmer, Christian Jackisch, Jens Huober, Elmar Stickeler, Mattea Reinisch, Theresa Link, Bruno Sinn, Wolfgang Janni, Carsten Denkert, Sabine Seiler, Christine Solbach, Sabine Schmatloch, Julia Rey, Sibylle Loibl
izdano v npj Breast Cancer (2024-07-01)

HER2-low status as a distinct breast cancer subtype: myth or truth? Analysis of the WSG trials WSG-ADAPT-HR+/HER2-, WSG-PlanB, and WSG-ADAPT-TN

od Gilda Schmidt, Oleg Gluz, Matthias Christgen, Mattea Reinisch, Sherko Kümmel, Ulrike Nitz, Michael Braun, Bahriye Aktas, Kerstin Lüdtke-Heckenkamp, Helmut Forstbauer, Eva-Maria Grischke, Claudia Schumacher, Rolf Mahlberg, Wolfram Malter, Toralf Reimer, Benno Nuding, Andrea Stefek, Rachel Wuerstlein, Monika Graeser, Katarzyna Jóźwiak, Sandy Burmeister, Christine zu Eulenburg, Michael Lauseker, Cornelia Kolberg-Liedtke, Aleix Prat, Peter Schmid, Rick Baehner, Hans Heinrich Kreipe, Erich-Franz Solomayer, Nadia Harbeck, on behalf of the West German Stud y Group investigators
izdano v Breast Cancer Research (2025-02-01)